Canagliflozin Alleviates Progestin Resistance by Suppressing RARβ/CRABP2 Signaling in THRB Knockout Endometrial Cancer Cells

    April 2025 in “ Frontiers in Pharmacology ”
    Ye Yang, Jieyun Zhou, Qiaoying Lv … Yan Zhu
    Studysummary This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Thyroid Receptor β: A Promising Target for Developing Novel Anti-Androgenetic Alopecia Drugs Drug discovery today · 2024